Allena Pharmaceuticals Inc. appointed Andrew Hack to the board.
Hack was earlier nominated to replace Stephen Kraus on the company's board. He currently serves as the CFO of Editas Medicine Inc.
Newton, Mass.-based Allena Pharmaceuticals develops oral enzyme therapeutics to treat rare and severe metabolic and kidney disorders.
